Art. -Nr.: HY-107818

4-Hydroxychalcone

2 Cited Publications

Kundenbewertung

Based on 2 publication(s) in Google Scholar

4-Hydroxychalcone is an orally active flavonoid precursor. 4-Hydroxychalcone inhibits VEGF- and bFGF-induced phosphorylation of ERK1/2 and Akt. 4-Hydroxychalcone suppresses resistant hypertension by alleviating hyperaldosteronism, inflammation and renal injury in cryptochrome gene knockout mice. 4-Hydroxychalcone possesses anti-angiogenic activity.\n

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.29%
CAS. Nr.: 20426-12-4
Formel: C₁₅H₁₂O₂
Molecular Weight:224.25

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

4-Hydroxychalcone Chemical Structure

CAS. Nr.: 20426-12-4

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

ERK1

ERK2

Alle ERK Isoform-spezifische Produkte anzeigen :

Alle Akt Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>20 μM Compound: 9e	Inhibition of TNFalpha induced NF-kappaB activation in human A549 cells by luciferase reporter gene assay Inhibition of TNFalpha induced NF-kappaB activation in human A549 cells by luciferase reporter gene assay	[PMID: 19883086]
A549	IC₅₀	26.6 μM Compound: 2	Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by CellTiter Aqueous One Solution MTS assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by CellTiter Aqueous One Solution MTS assay	[PMID: 37666364]
CCRF-CEM	IC₅₀	9.31 μM Compound: 32	Concentration required to inhibit 50% growth of Human CEM T-lymphocytes cells Concentration required to inhibit 50% growth of Human CEM T-lymphocytes cells	[PMID: 9544201]
DLD-1	EC₅₀	51 μM Compound: 8	Cytotoxicity against human DLD-1 cells assessed as reduction in cell viability incubated for 48 hrs by AlamarBlue-based assay Cytotoxicity against human DLD-1 cells assessed as reduction in cell viability incubated for 48 hrs by AlamarBlue-based assay	[PMID: 36356534]
FHC	CC₅₀	>100 μM Compound: 8	Cytotoxicity against human FHC cells assessed as reduction in cell viability incubated for 48 hrs by AlamarBlue-based assay Cytotoxicity against human FHC cells assessed as reduction in cell viability incubated for 48 hrs by AlamarBlue-based assay	[PMID: 36356534]
HCT-116	EC₅₀	32 μM Compound: 8	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by AlamarBlue-based assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by AlamarBlue-based assay	[PMID: 36356534]
HCT-116	EC₅₀	32 μM Compound: 8	Cytotoxicity against p53-/- human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by AlamarBlue-based assay Cytotoxicity against p53-/- human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by AlamarBlue-based assay	[PMID: 36356534]
HEK293	IC₅₀	>50 μM Compound: 2	Blockade of human K+ channel in HEK293 cells assessed as inhibition of outward delayed rectifying K+ current Blockade of human K+ channel in HEK293 cells assessed as inhibition of outward delayed rectifying K+ current	[PMID: 18032041]
HT-29	EC₅₀	39 μM Compound: 8	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by AlamarBlue-based assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by AlamarBlue-based assay	[PMID: 36356534]
HT-29	IC₅₀	24.6 μM Compound: 16	Cytotoxicity against Homo sapiens (human) HT-29 cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) HT-29 cells after 72 hr by MTT assay	10.1007/s00044-011-9549-9
K562	IC₅₀	24 μM Compound: 4-Hydroxychalcone	Inhibition of NF-kappaB transactivation in TNF-alpha-stimulated human K562 cells preincubated for 2 hrs followed by TNF-alpha challenge measured after 6 hrs by dual luciferase reporter gene assay Inhibition of NF-kappaB transactivation in TNF-alpha-stimulated human K562 cells preincubated for 2 hrs followed by TNF-alpha challenge measured after 6 hrs by dual luciferase reporter gene assay	[PMID: 24775915]
L1210	IC₅₀	37.9 μM Compound: 32	Concentration required to inhibit 50% growth of L1210 leukemia cells Concentration required to inhibit 50% growth of L1210 leukemia cells	[PMID: 9544201]
Neutrophil	IC₅₀	11.6 μM Compound: 25	Inhibition of PMA-induce ROS/RNS generation in human neutrophils measured up to 30 mins in presence of 30 mM glucose by luminol-amplified chemiluminescence method Inhibition of PMA-induce ROS/RNS generation in human neutrophils measured up to 30 mins in presence of 30 mM glucose by luminol-amplified chemiluminescence method	[PMID: 33006891]
Neutrophil	IC₅₀	8.8 μM Compound: 25	Inhibition of PMA-induce ROS/RNS generation in human neutrophils measured up to 30 mins in presence of 5.5 mM glucose by luminol-amplified chemiluminescence method Inhibition of PMA-induce ROS/RNS generation in human neutrophils measured up to 30 mins in presence of 5.5 mM glucose by luminol-amplified chemiluminescence method	[PMID: 33006891]
NIH3T3	IC₅₀	>20 μM Compound: 1i	Inhibition of cobalt chloride-induced HIF-1 activation expressed in mouse NIH3T3 cells after 8 hrs by luciferase reporter gene assay Inhibition of cobalt chloride-induced HIF-1 activation expressed in mouse NIH3T3 cells after 8 hrs by luciferase reporter gene assay	[PMID: 21112783]
P388	IC₅₀	14.3 μM Compound: 32	Inhibition of proliferation of murine P388 cells Inhibition of proliferation of murine P388 cells	[PMID: 9544201]
SGC-7901	IC₅₀	13.74 μM Compound: 16	Cytotoxicity against Homo sapiens (human) SGC7901 cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) SGC7901 cells after 72 hr by MTT assay	10.1007/s00044-011-9549-9

In Vitro

4-hydroxychalcone (22 µg/mL; 6 days) potently inhibits VEGF/TNF-α- and bFGF/TNF-α-induced capillary-like tube formation of hMVEC in 3D fibrin matrices, with no cytotoxicity to endothelial monolayers^[1].
4-hydroxychalcone (0.22-22 µg/mL; 24-144 h) exhibits no cytotoxicity toward confluent HUVEC and hMVEC monolayers^[1].
4-hydroxychalcone (0.22-22 µg/mL; 48-72 h) exerts a cytostatic effect on the proliferation of HUVEC, but shows no cytostatic effect on HeLa, MCF-7 or A549 tumor cell lines even at a concentration as high as 22 µg/mL with a 72 h treatment^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

human umbilical vein endothelial cells (HUVEC)
Concentration:

2.2-22 µg/mL
Incubation Time:

1 h pre-incubation
Result:

Significantly inhibited both bFGF- and VEGF-induced phosphorylation of Akt and ERK1/2 in HUVEC at 22 µg/mL.
Significantly inhibited VEGF-induced phosphorylation of ERK1/2, but not Akt, in HUVEC at 2.2 µg/mL.

Immunofluorescence^[1]

Cell Line:

human umbilical vein endothelial cells (HUVEC)
Concentration:

22 µg/mL
Incubation Time:

1 h pre-incubation, followed by 1 h TNF-α stimulation
Result:

Had no effect on TNF-α-induced nuclear translocation of the p65 subunit of NF-κB in HUVEC.

In Vivo

4-Hydroxychalcone (5.6 µg/mL; topical application) significantly inhibits bFGF-induced angiogenesis in the chick chorioallantoic membrane assay, without impairing basal vascular formation or embryonic survival^[1].
4-Hydroxychalcone (10-40 mg/kg; p.o.; twice daily; for consecutive 35 days) exerts dose-dependent protective effects against refractory hypertension, hyperaldosteronism, inflammation and renal injury in cryptochrome-knockout mice treated with high salt^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Cryptochrome-null mice (male/female unspecified; high-salt diet-induced hypertension, hyperaldosteronism, inflammation, renal injury model)^[2]
Dosage:

10 mg/kg; 20 mg/kg; 40 mg/kg
Administration:

p.o.; twice daily; 35 days
Result:

Produced no significant change in systolic blood pressure compared to untreated cryptochrome-null mice; significantly reduced serum IL-1β levels compared to untreated cryptochrome-null mice (P < 0.05); did not significantly reduce serum TNF-α levels, serum aldosterone levels, renal NF-κB activation, or renal injury.
Produced no significant change in systolic blood pressure compared to untreated cryptochrome-null mice; significantly reduced serum IL-1β levels compared to untreated cryptochrome-null mice (P < 0.01); significantly reduced serum aldosterone levels compared to untreated cryptochrome-null mice (P < 0.05); did not significantly reduce serum TNF-α levels, renal NF-κB activation, or renal injury.
Significantly lowered systolic blood pressure in cryptochrome-null mice compared to untreated controls (P < 0.05); significantly reduced serum aldosterone levels compared to untreated cryptochrome-null mice (P < 0.01); significantly reduced serum IL-1β levels compared to untreated cryptochrome-null mice (P < 0.01); significantly suppressed serum TNF-α production compared to untreated cryptochrome-null mice (P < 0.05); reduced renal NF-κB protein activation in kidney cell nuclei compared to untreated cryptochrome-null mice; dramatically reduced severe glomerulosclerosis, tubulointerstitial injury, and inflammatory cell infiltration in kidney tissue compared to untreated cryptochrome-null mice, resulting in more normal histology.

Chemical Information

CAS. Nr. 20426-12-4
Appearance Solid
Molecular Weight 224.25
Formel C₁₅H₁₂O₂
Color Light yellow to yellow
SMILES

O=C(C1=CC=CC=C1)/C=C/C2=CC=C(O)C=C2
Structure Classification
- Flavonoids
- Chalcones
- Phenols
- Monophenols
Initial Source
- Plants
- other families
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (2)

All

Sort by:

Journal Impact Factor

Food Chem

Effects of sun drying combined with baking processes on the flavor quality of Chongqing Tuocha raw tea. [Abstract]

2025 Dec 30:497:146992. PMID: 41285060
Food Chem

Flavonoid-mediated metabolic underpinning quality variation in red bud-sport pear mutants. [Abstract]

2025 May 31:489:144992. PMID: 40466530

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (445.93 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.4593 mL

22.2965 mL

44.5931 mL

5 mM

0.8919 mL

4.4593 mL

8.9186 mL

10 mM

0.4459 mL

2.2297 mL

4.4593 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (9.28 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (9.28 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (538 KB)
- English - EN (538 KB)
- Français - FR (538 KB)
- Deutsch - DE (538 KB)
- Norwegian - NO (538 KB)
- Español - ES (538 KB)
- Swedish - SV (538 KB)
- Italian - IT (538 KB)
- Korean - KR (538 KB)
- Portuguese - PT (538 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Varinska L, et al. Anti-angiogenic activity of the flavonoid precursor 4-hydroxychalcone. Eur J Pharmacol. 2012;691(1-3):125-133. [Content Brief]

[2]. Qu Q, et al. 4-Hydroxychalcone attenuates hyperaldosteronism, inflammation, and renal injury in cryptochrome-null mice. Biomed Res Int. 2014;2014:603415. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.4593 mL	22.2965 mL	44.5931 mL	111.4827 mL
	5 mM	0.8919 mL	4.4593 mL	8.9186 mL	22.2965 mL
	10 mM	0.4459 mL	2.2297 mL	4.4593 mL	11.1483 mL
	15 mM	0.2973 mL	1.4864 mL	2.9729 mL	7.4322 mL
	20 mM	0.2230 mL	1.1148 mL	2.2297 mL	5.5741 mL
	25 mM	0.1784 mL	0.8919 mL	1.7837 mL	4.4593 mL
	30 mM	0.1486 mL	0.7432 mL	1.4864 mL	3.7161 mL
	40 mM	0.1115 mL	0.5574 mL	1.1148 mL	2.7871 mL
	50 mM	0.0892 mL	0.4459 mL	0.8919 mL	2.2297 mL
	60 mM	0.0743 mL	0.3716 mL	0.7432 mL	1.8580 mL
	80 mM	0.0557 mL	0.2787 mL	0.5574 mL	1.3935 mL
	100 mM	0.0446 mL	0.2230 mL	0.4459 mL	1.1148 mL

Keywords

4-Hydroxychalcone

2 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

4-Hydroxychalcone

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Autophagy Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Endocrinology Compound Library

Phenols Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Flavonoids Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Serine/Threonine Kinase Inhibitor Library

Anti-Drug-Resistant Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

Flavor Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) 4-Hydroxychalcone

Alle ERK Isoform-spezifische Produkte anzeigen

Alle Akt Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (2)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

4-Hydroxychalcone Related Classifications

HY-107818 Related Classifications